<code id='437436F8B7'></code><style id='437436F8B7'></style>
    • <acronym id='437436F8B7'></acronym>
      <center id='437436F8B7'><center id='437436F8B7'><tfoot id='437436F8B7'></tfoot></center><abbr id='437436F8B7'><dir id='437436F8B7'><tfoot id='437436F8B7'></tfoot><noframes id='437436F8B7'>

    • <optgroup id='437436F8B7'><strike id='437436F8B7'><sup id='437436F8B7'></sup></strike><code id='437436F8B7'></code></optgroup>
        1. <b id='437436F8B7'><label id='437436F8B7'><select id='437436F8B7'><dt id='437436F8B7'><span id='437436F8B7'></span></dt></select></label></b><u id='437436F8B7'></u>
          <i id='437436F8B7'><strike id='437436F8B7'><tt id='437436F8B7'><pre id='437436F8B7'></pre></tt></strike></i>

          
          WSS
          3d heart myocarditis
          Adobe

          Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

          If things go well, Roche could pay Alnylam up to $2.8 billion in total.

          advertisement

          Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia